PARPi monotherapy has been shown to potently induce STING (stimulator of IFN genes)-mediated anti-tumour immune responses as well as activate the PD-1/PD-L1 immune checkpoint pathway in various cancer models20–22 including BRCA-mutant TNBC23,24. This evidence concerns the gene PDCD1 and neoplasm.